Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 32

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Dermatitis atopic89Malignant melanoma79Systemic lupus erythematosus63Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma40Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Basal cell carcinoma12Diabetic foot12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+335

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Actinic keratosis

Not yet recruiting

Study on Cryotherapy and Tirbanibulin for Treating Actinic Keratosis on the Scalp and Forehead in Patients Aged 18 and Older

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tirbanibulin
  • Sponsor:Centre Hospitalier Universitaire De Lille

Skin squamous cell carcinoma metastatic+1

Not yet recruiting

Study of INCB099280 for Patients With Advanced Cutaneous Squamous Cell Carcinoma Not Suitable for Surgery or Radiotherapy

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280
  • Sponsor:Incyte Corp.

Chronic kidney disease-associated pruritus

Not yet recruiting

Evaluation of MC2-25 Cream for Itching in Patients with Chronic Kidney Disease-associated Pruritus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Mc2 Therapeutics Limited

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Immunoglobulin G4 related disease+3

Not yet recruiting

Study on the Safety and Effectiveness of Filgotinib for Patients with Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Diabetic foot

Not yet recruiting

Study Comparing Propylene Glycol and Urea Creams for Treating Dry Feet in People with Diabetes

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Propylene Glycol
  • Sponsor:Malmoe Universitet

Vitiligo

Not yet recruiting

Study on Pioglitazone for Adults with Non-Segmental Vitiligo

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Pioglitazone
  • Sponsor:I.F.O. Istituti Fisioterapici Ospitalieri

Systemic lupus erythematosus

Not recruiting

Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:UCB Biopharma

Dermatitis atopic

Not recruiting

A Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

Dermatitis acneiform

Not recruiting

A study testing aprepitant gel for treating skin rash in cancer patients receiving epidermal growth factor receptor inhibitor therapy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Hoth Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.